Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney, and thyroid cancers using its investigational therapy LP-184 (zirdafulven). The allowed claims focus on a three-gene biomarker signature comprising elevated expression of PTGR1, PTPN14, and ASPH to identify patients likely to benefit from LP-184 treatment.
The patent allowance is a significant milestone for the company, as it strengthens Lantern's intellectual property portfolio and supports the precision medicine approach for LP-184. The biomarker signature was identified using Lantern's proprietary RADR artificial intelligence platform, which analyzes vast datasets to uncover patient-specific treatment strategies. This approach aims to improve therapeutic outcomes by matching patients with the most effective therapies based on their genetic profiles.
Lantern reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial of LP-184. The company plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026, targeting cancers where the biomarker signature is prevalent. This progress highlights the potential of AI-driven drug development to accelerate the creation of targeted cancer treatments.
The patent allowance also underscores the broader implications for precision oncology. By using biomarkers to stratify patients, Lantern aims to increase treatment efficacy and reduce unnecessary side effects. The RADR platform's ability to identify novel biomarkers positions the company as a leader in integrating artificial intelligence into cancer drug development.
For more details, visit the full press release at https://ibn.fm/LRGUo. Lantern Pharma continues to expand its pipeline, which includes other investigational therapies like LP-284 and LP-300, and its AI co-scientist platform, withZeta.ai, is now commercially available.
